Becerra, M. C., S. C. Appleton, M. F. Franke, K. Chalco, F. Arteaga, J. Bayona, M. Murray, S. S. Atwood, and C. D. Mitnick. 2011. Tuberculosis burden in households of patients with multidrug-resistant and extensively drug-resistant tuberculosis: A retrospective cohort study. Lancet 377(9760):147–152.

Being brave: Stories of children with drug-resistant tuberculosis. 2012. The Sentinel Project for Pediatric Drug-Resistant Tuberculosis. (accessed April 15, 2013).

Blanc, F. X., T. Sok, D. Laureillard, L. Borand, C. Rekacewicz, E. Nerrienet, Y. Madec, O. Marcy, S. Chan, N. Prak, C. Kim, K. K. Lak, C. Hak, B. Dim, C. I. Sin, S. Sun, B. Guillard, B. Sar, S. Vong, M. Fernandez, L. Fox, J. F. Delfraissy, A. E. Goldfeld, and the CAMELIA (ANRS 1295–CIPRA KH001) Study Team. 2011. Earlier versus later start of antiretroviral therapy in HIV-infected adults with tuberculosis. New England Journal of Medicine 365(16):1471–1481.

Boccia, D., J. Hargreaves, K. Lonnroth, E. Jaramillo, J. Weiss, M. Uplekar, J. D. Porter, and C. A. Evans. 2011. Cash transfer and microfinance interventions for tuberculosis control: Review of the impact evidence and policy implications. International Journal of Tuberculosis and Lung Disease 15(Suppl 2): S37–S49.

Böttger, E. C. 2011. The ins and outs of Mycobacterium tuberculosis drug susceptibility testing. Clinical Microbiology and Infection 17(8):1128–1134.

Cegielski, P., P. Nunn, E. V. Kurbatova, K. Weyer, T. L. Dalton, D. F. Wares, M. F. Iademarco, K. G. Castro, and M. Raviglione. 2012. Challenges and controversies in defining totally drug-resistant tuberculosis. Emerging Infectious Diseases 18(11):e2.

Chaisson, R. E. 2013. Addressing the spectrum of drug-resistant TB: Clinical perspective. Presentation at the IOM workshop on the Global Crisis of Drug-Resistant Tuberculosis and the Leadership of the BRICS Countries: Challenges and Opportunities, January 16–18, Beijing, China.

Chen, M. 2013. Programmatic management of MDR-TB in China: Progress, plan and challenge. Presentation at the IOM workshop on the Global Crisis of Drug-Resistant Tuberculosis and the Leadership of the BRICS Countries: Challenges and Opportunities, January 16–18, Beijing, China.

Cohen, T., M. Murray, K. Wallengren, G. G. Alvarez, E. Y. Samuel, and D. Wilson. 2010. The prevalence and drug sensitivity of tuberculosis among patients dying in hospital in KwaZulu-Natal, South Africa: A postmortem study. PLoS Medicine 7(6).

Comas, I., and S. Gagneux. 2009. The past and future of tuberculosis research. PLoS Pathogens 5(10):e1000600.

Comas, I., S. Borrell, A. Roetzer, G. Rose, B. Malla, M. Kato-Maeda, J. Galagan, S. Niemann, and S. Gagneux. 2011. Whole-genome sequencing of rifampicin-resistant Mycobacterium tuberculosis strains identifies compensatory mutations in RNA polymerase genes. Nature Genetics 44(1):106–110.

Dalton, T., P. Cegielski, S. Akksilp, L. Asencios, J. Campos Caoili, S. N. Cho, V. V. Erokhin, J. Ershova, M. T. Gler, B. Y. Kazennyy, H. J. Kim, K. Kliiman, E. Kurbatova, C. Kvasnovsky, V. Leimane, M. van der Walt, L. E. Via, G. V. Volchenkov, M. A. Yagui, H. Kang, and the Global PETTS Investigators. 2012. Prevalence of and risk factors for resistance to second-line drugs in people with multidrug-resistant tuberculosis in eight countries: A prospective cohort study. Lancet 380(9851):1406–1417.

Deng, Y., Y. Wang, J. Wang, H. Jing, C. Yu, H. Wang, Z. Liu, E. A. Graviss, and X. Ma. 2011. Laboratory-based surveillance of extensively drug-resistant tuberculosis, China. Emerging Infectious Diseases 17(3):495–497.

Devaux, I., K. Kremer, H. Heersma, and D. Van Soolingen. 2009. Clusters of multidrug-resistant Mycobacterium tuberculosis cases, Europe. Emerging Infectious Diseases 15(7):1052–1060. (accessed November 25, 2013).

The National Academies | 500 Fifth St. N.W. | Washington, D.C. 20001
Copyright © National Academy of Sciences. All rights reserved.
Terms of Use and Privacy Statement